Search Results for: Dopamine

October 13, 2019October 13, 2019

The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

Publication date: Oct 09, 2019 The G2019S substitution in the kinase domain of LRRK2 (LRRK2) is the most prevalent mutation associated with Parkinson’s disease (PD). Neurotoxic effects of LRRK2 are ... Read more

October 12, 2019

Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson’s disease.

Parkinson's Disease Literature

Publication date: Oct 11, 2019 Reduced levels of dopamine in Parkinson’s disease contribute to changes in learning, resulting from the loss of midbrain neurons that transmit a dopaminergic teaching signal ... Read more

October 5, 2019

Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinson’s disease with mild cognitive impairment.

Parkinson's Disease Literature

Publication date: Oct 02, 2019 Cognitive impairment is a common non-motor feature of Parkinson’s disease (PD). However, the underlying pathophysiology of cognitive decline is unclear. We investigated the association of ... Read more

October 5, 2019October 5, 2019

Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons.

Parkinson's Disease Literature

Publication date: Oct 03, 2019 Cellular senescence is a mechanism used by mitotic cells to prevent uncontrolled cell division. As senescent cells persist in tissues, they cause local inflammation and ... Read more

October 5, 2019October 5, 2019

Exercise increases caudate dopamine release and ventral striatal activation in Parkinson’s disease.

Parkinson's Disease Literature

Publication date: Oct 04, 2019 The objective of this study was to examine the effects of aerobic exercise on evoked dopamine release and activity of the ventral striatum using positron ... Read more

October 4, 2019October 4, 2019

Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors.

Parkinson's Disease Literature

Publication date: Oct 03, 2019 There are growing reports of dopamine agonist (DA)-induced impulse control disorders (ICDs) in hyperprolactinemic patients. However, the magnitude of this risk and predictive factors remain ... Read more

October 4, 2019October 4, 2019

ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson’s disease.

Parkinson's Disease Literature

Publication date: Oct 02, 2019 Dopamine deficiency is mainly caused by apoptosis of dopaminergic nerve cells in the substantia nigra of the midbrain and the striatum and is an important ... Read more

September 4, 2019September 4, 2019

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.

Melanoma Literature

Publication date: Sep 02, 2019 In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers ... Read more

July 16, 2019July 16, 2019

Dysfunctional striatal dopamine signaling in Huntington’s disease.

Huntington's Disease Literature

Publication date: Jul 15, 2019 Dopamine signaling in the striatum is critical for a variety of behaviors including movement, behavioral flexibility, response to reward and many forms of learning. Alterations ... Read more

July 1, 2019July 1, 2019

Dopamine DR antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects.

Opioids Literature

Publication date: Jul 01, 2019 Prescription opioids such as oxycodone are highly effective analgesics for clinical pain management, but their misuse and abuse have led to the current opioid epidemic ... Read more